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ABSTRACT
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Introduction: Spasticity is a motor disorder characterized by a velocity-dependent
increase in tonic stretch reflexes. The gold standard for assessing spasticity in stroke patients is
the Modified Ashworth Scale (MAS), but the scale is highly subjective to the clinician’s opinion
and previous experience and lacks psychometric fidelity. Numerous studies have criticized the
scale’s subjectivity and lack of rater reliability. Development of a quantitative spasticity device
in routine clinical care is warranted. Before doing so, however, it is important to examine how
MAS scores translate into functional measures and quantitative kinematic and/or kinetic values.
Methods: Data from 20 subjects (6 female, 14 male; mean age 57 ± 10) with chronic
hemiparesis secondary to a cerebrovascular accident (stroke) were used to examine the
relationships between the MAS and residual impairments (active range of motion of shoulder
flexion, elbow, and wrist, and muscle strength of the elbow flexion and extension), the MAS and
functional limitations as measured by the Fugl-Meyer upper extremity assessment, finger to nose
movement, the MAS and overall health status following stroke as measured by the Stroke Impact
Scale, and to inspect whether there are potential kinematic values or physiological responses that
can be used to identify the characteristics of the passive stretch (passive stretch duration, catch
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angle, electromyography response). The data were collected at both the Rehabilitation Institute
of Chicago and the University of Wisconsin-Milwaukee.
Results: Overall, results showed that stroke subjects who had more severe spasticity
tended to have reduced range of motion at the shoulder (flexion) (Pearson correlation coefficient
rp = -.601; Spearman correlation coefficient rs = -.607), elbow (rp = -.436; rs = -.495) and wrist (rp
= -.206; rs = -.305) joints, as well as reduced muscle strength for elbow flexion (rp = -.547; rs = .618). The relationship between the MAS scores and the muscle strength for elbow extension
was weak (rp = -.160; rs = -.191). Analysis between the FM-UE subscale and MAS revealed a
significant negative correlation. The strongest correlation occurred between the FM-UE total
score (rp = -0.817; rs = -0.806), while the weakest correlation amongst all subscales occurred
between coordination subscale (rp = -0.696; rs = -0.684). A one-way, between-subjects design
ANOVA showed significant mean differences between MAS scores and all FM-UE subscales:
the FM-Arm subscale (F4,15 = 17.4, p < .001), the FM-Wrist subscale (F4,15 = 4.3, p < 0.016), the
FM-Hand subscale (F4,15 = 4.8, p < 0.011), the FM-Corr subscale (F4,15 = 4.4, p < 0.015) as well
as FM-Total Score subscale (F4,15 = 12.6, p < 0.001). Overall, there was a tendency for increased
levels of spasticity per scoring of the MAS to result in decreased motor performance as measured
by the FM-UE subscale. There was a moderate negative correlation between MAS score and the
Stroke Index Scale hand subscale (rp = -0.543; rs = -0.576), indicating that a higher MAS score
may be indicative of the magnitude of impairment in the hand. No significant relationships were
demonstrated between the remaining subscales of the Stroke Impact Scale, suggesting that there
is little to no relationship between MAS scores and overall health status. In comparing EMG
activity and motion capture analysis, there was a marked increase in the EMG response when the
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subjects affected limb is stretched into full elbow extension, such phenomenon was not observed
when stretching the unaffected limb.
Conclusion: The strong correlation between MAS scores and the residual impairments as
well as the FM-UE subscale suggests that a higher MAS score may be indicative of the general
stage of motor recovery following incurrence of a stroke. Additionally, there was a marked
increase in EMG activity through passive stretching of the affected limb into full elbow
extension; conversely, such a phenomenon was not observed in the unaffected limb.
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I. Introduction
Background
Spasticity is a feature of altered skeletal muscle performance involving hypertonia, and
has been described as one of the most debilitating complications of neurologic conditions in
patients with stroke, brain injury, spinal cord injury, cerebral palsy, or multiple sclerosis. Cohort
studies have revealed that 20-40% of stroke survivors are spastic (Leathley et al., 2004;
Sommerfeld, Eek, Svensson, Holmqvist, & von Arbin, 2004; Watkins et al., 2002). Patients with
spasticity may experience painful spasms, increased muscle stiffness, and loss of joint range of
motion (Botte, Nickel, & Akeson, 1988; Ivanhoe, Francisco, McGuire, Subramanian, &
Grissom, 2006; Kamper, Schmit, & Rymer, 2001). Severe spasticity may cause functional
challenges in various aspects of daily living such as dressing, self-cares, and eating (Bhimani &
Anderson, 2014; Jagatsinh, 2009; Katz & Rymer, 1989; Zorowitz, Gillard, & Brainin, 2013).
Furthermore, prolonged spasticity that typically persists for 12 months or more after stroke may
lead to postural deformity and contracture. The interaction between neural and biomechanical
components of spasticity and its potential impact on functional limitation has been described by
Barnes & Johnson (Figure 1).
Modified Ashworth Scale
The Modified Ashworth Scale (MAS), modified from the Ashworth (AS) Scale, is the
most commonly utilized clinical measure of quantifying spasticity (Table 1) (Ashworth, 1964;
Bohannon & Smith, 1987). The original Ashworth Scale introduced in 1964 was constructed
using a 5-point ordinal scale, with a Likert-like grade score of 0 (indicating no increase in muscle
tone), 1, 2, 3, or 4 (affected part rigid in flexion or extension) to quantify spasticity. In 1987,
Bohannon and Smith introduced the grade of “1+” and proposed slight changes in how each
score was defined in order to increase the sensitivity of the measure and facilitate greater ease in
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scoring, which prompted the renaming of the Ashworth Scale as the “Modified Ashworth Scale”
(Bohannon & Smith, 1987). To evaluate elbow spasticity using the MAS, for example, the
clinician quickly and passively stretches the patient’s affected elbow. The clinician would
support the patient’s affected extremity at the elbow joint in 90 degrees of shoulder abduction
while placing the other available hand on the volar aspect of the patient’s wrist to provide
support. The clinician begins by bringing the patient’s elbow into maximum flexion, quickly
stretching the elbow into maximum extension to assess flexor spasticity (i.e., stretching the
biceps muscle), and finally moving the elbow back into the starting position of maximum elbow
flexion to assess extensor spasticity (i.e., stretching the triceps muscle).
The MAS, although simple to administer and convenient, has been criticized. Briefly, it is
highly subjective to the clinician’s personal experience and the velocity at which the affected
extremity is passively stretched. Some studies showed that the scale lacks inter-rater reliability
(e.g., inter-rater reliability: mean = 0.56-0.76, agreement = 66%, 59-78%, intra-rater reliability =
32%, 62-72%) (Blackburn, van Vliet, & Mockett, 2002; Fleuren et al., 2010; Gregson et al.,
1999; Gregson et al., 2000; Sloan, Sinclair, Thompson, Taylor, & Pentland, 1992). Studies have
illustrated that the MAS also suffers from a clustering effect wherein most of the patients are
grouped within the middle grades (Damiano et al., 2002). The MAS scores were not significantly
associated with electromyography changes and only moderately associated with resistance.
Ambiguity of wording and lack of standardized procedures limit the scale’s usefulness for
comparison across studies. There are no clear guidelines for stretching velocity during
administration of the MAS. It is possible that variable stretching velocities can affect the
elicitation of spasticity. There is also poor scale sensitivity to change for rigorous clinical and
research application. Overall, studies showed that reliability differs from muscle to muscle, and
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suggested that assessment technique must be standardized and adequate training is required to
ensure inter-rater reliability.
Additional studies have challenged the scale’s validity, contending that it does not
adequately distinguish between neurological and mechanical factors that contribute to joint
stiffness (Kumar, Pandyan, & Sharma, 2006; Pandyan et al., 1999; Platz, Eickhof, Nuyens, &
Vuadens, 2005). Furthermore, the MAS does not account for skeletal muscle changes, such as
contractures, which are not necessarily attributable to spasticity alone (Foran, Steinman, Barash,
Chambers, & Lieber, 2005).
Numerous studies have explored the relationship between MAS scores and
neurophysiological variables. In particular, a study led by Cooper et al. produced findings that
indicated a positive correlation of MAS scores with magnitude and duration of surface
electromyography response. The authors concluded that this finding is evidential that the MAS
reflects spasticity in terms of surface electromyography response during passive stretch (Cooper,
Musa, van Deursen, & Wiles, 2005). Similar studies have sought to corroborate this contention,
but have only found moderate associations between MAS scores and electromyography,
indicating that the scale may be more of a measure of hypertonia rather than spasticity (Bakheit,
Maynard, Curnow, Hudson, & Kodapala, 2003; Lin & Sabbahi, 1999; Pisano et al., 2000; Skold,
Harms-Ringdahl, Hultling, Levi, & Seiger, 1998). Instead, a more significant relationship was
yielded in other studies that examined the relationship between MAS scores and objective
measurements of resistance to passive movement, again elucidating what the MAS is actually
constructed to measure. While utilization of descriptive measures such as the MAS continues,
measures that provide the clinician with neurophysiological characteristics has been advocated. It
is clear that discrepancies between clinical measures like the MAS and real neurophysiological
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measures (i.e., surface electromyography) persist. Bridging this gap is critical to provision of
appropriate anti-spasticity treatment.
Current research trends suggest that there is a substantial effort underway to discover
novel therapeutic technologies and strategies to treat spasticity (Bhakta, Cozens, Chamberlain, &
Bamford, 2000; Brashear et al., 2002; Phadke, On, Kirazli, Ismail, & Boulias, 2013; Pittock et
al., 2003; Remy-Neris, Tiffreau, Bouilland, & Bussel, 2003; Shakespeare, Boggild, & Young,
2003). A host of clinical studies examining the effects of surgical, pharmacological, or
therapeutic spasticity interventions refer to the MAS as an outcome measure (Bohannon &
Smith, 1987). One particular study by Ivanhoe et al. examined the effects of intrathecal baclofen
and produced positive results demonstrating a reduction in subjects’ spasticity per scoring of the
MAS (Ivanhoe et al., 2006). However, an ordinal scale such as the MAS may lack sensitivity and
precision for noting smaller degrees of change in spasticity, thus making it difficult to
corroborate the study’s conclusions and subsequently limiting clinical application of its findings.
Likewise, other studies examining the effect of surgical intervention in individuals with cerebral
palsy have produced lower MAS scores (Butler & Campbell, 2000; McLaughlin et al., 1998),
purporting that the surgical intervention was successful. The generalizability of these studies, and
others alike, is inconspicuous due to the limitations of the MAS. Because the MAS is highly
subjective to the clinician’s personal opinion, some researchers have contended that clinicians
stop using the Ashworth Scale for the assessment of spasticity (Fleuren et al., 2010).
Clinical Significance
Stroke is the leading cause of disability in the adult population, affecting over 4 million
people in the United States alone (Hinojosa, Rittman, & Hinojosa, 2009). More than one out of
every four patients develops spasticity after experiencing a stroke (Wissel et al., 2010). As a
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serious detriment to daily function and quality of life, proper management of spasticity is an
important component of many rehabilitation protocols. Spasticity is a complex
pathophysiological phenomenon, and, as such, should not rely on a subjective scale for
quantification.
Although reliability and validity of the MAS has been criticized, currently there is no
clinical measurement that outperforms the MAS in quantifying spasticity (Blackburn et al., 2002;
Gregson et al., 1999; Pandyan et al., 1999). One solution in advancing the spasticity measure is
to improve the precision during administering the MAS by taking away the subjective factor
(i.e., develop a quantitative spasticity device in routine clinical care). Increased objectivity in the
quantification of spasticity has the potential to assist physicians and therapists in anti-spasticity
management and more accurately illustrate the effects of interventions that have otherwise been
deemed as ineffective or inconclusive.
Specific Aims
Before developing a quantitative spasticity device in routine clinical care, it is important
to understand how the MAS scores translate into functional measures and quantitative kinematic
and/or kinetic values. As the first step, we proposed to conduct a pilot study. Our specific aims
are:
1. To examine the relationships between the MAS and residual impairments (active range of
motion of shoulder flexion, elbow, and wrist, and muscle strength of the elbow flexion
and extension).
2. To explore the relationships between the MAS and functional limitations as measured by
Fugl-Meyer upper extremity assessment, finger to nose movement, and ability to grasp a
bottle of water.
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3. To investigate the relationship between the MAS and overall health status following
stroke as measured by the Stroke Impact Scale.
For aims 1 to 3: Data from 20 subjects (6 female, 14 male; mean age 57 ± 10) with chronic
hemiparesis secondary to a cerebrovascular accident (stroke) will be used to examine the
relationships. The data were collected at the Rehabilitation Institute of Chicago.
4. To inspect whether there are potential kinematic values or physiological responses that
can be used to identify the characteristics of the passive stretch (passive stretch duration,
catch angle, electromyography response).
For aim 4: A case study will be used to inspect the graphical presentation of the kinematics
during passive stretching. The data were collected at the University of Wisconsin-Milwaukee.

II. Literature Review
Pathophysiology of Stroke
Cerebrovascular accident (CVA), commonly known as simply stroke, is a neurological
event characterized by an abrupt disruption in cerebral circulation producing an array of
neurological deficits. While the neurological mechanisms of stroke are widely variable, stroke is
delineated into two broad categories (ischemic stroke and hemorrhagic stroke) based on clinical
manifestation of symptoms.
Ischemic strokes occur when there is a disruption in blood flow in the brain for seconds
or minutes, resulting in infarction (cell death). Infarction occurs if the brain is deprived of
circulation for more than a few minutes. It could due to atherosclerosis, excess plaque buildup in
the aortic arch, carotid arteries, or cerebral vessels, or emboli, traveling intravascular masses in
the arteries. The most common precipitating event of cardioembolic strokes is occlusion of the
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middle cerebral artery or the posterior cerebral artery in the brain. Unlike atherosclerotic events,
symptoms that are produced from an embolus are often more sudden, producing severe,
observable neurological deficits. Regardless of etiology, the clinical presentation in cerebral
ischemic/infarction events is predicated upon the site of occlusion in the artery. Common clinical
presentation of ischemic stroke includes but is not limited to weakness and loss of sensation in
the contralateral leg and foot, contralateral sensory loss and weakness, loss of the nasal half of
vision on the opposite side and loss of the temporal half of vision on the same side, aphasia,
neglect, ataxia, vertigo, hiccupping, and difficulty swallowing (Frizzell, 2005).
Hemorrhagic strokes are the third most common cause of stroke and are associated with
about a 50% mortality rate. These occur when there is a leak or rupture in a vessel causing
intracerebral bleeding, commonly in the basal ganglia, thalamus, pons, and cerebellum. The
onset of hemorrhagic strokes can be both non-traumatic and traumatic in nature. Neurological
deficits are dependent upon the site and severity of the hemorrhage and typically appear
abruptly, developing over of a span of 30 to 90 minutes. The most severe deficits typically
present within hours of onset, with gradual improve as edema subsides and extravascular blood
is removed (Frizzell, 2005).
Pathophysiology of Spasticity
Spasticity is a form of hypertonia, or excess muscle tone, classically defined by Lance
(1980) as an increased resistance to a passive stretch. The increased resistance is a result of a
velocity-dependent increase in tonic stretch reflexes that occurs from hyper-excitability of the
stretch reflex, which is one component of the upper motor neuron syndrome (Lance, 1980). In a
2001 interdisciplinary workshop sponsored by the National Institutes of Health, spasticity was
defined as hypertonia with either one or both of the following present: (1) resistance to externally
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imposed movement that increases with increasing speed of stretch and varies with the direction
of joint movement or (2) resistance to externally imposed movement increases above a threshold
speed or joint angle (Sanger et al., 2003). Other proposed mechanisms of spasticity include
fusimotor neuron hyperactivity, hyperexcitable motor neurons, abnormal excitability of the
spinal segmental and intersegmental interneurons from loss of supraspinal influences, as well as
changes in the properties of the muscles themselves (Sehgal & McGuire, 1998). Newer research
has refined this definition suggesting that spasticity is also a sensorimotor phenomenon with
other alterations present in the central nervous system as part of the upper motor neuron
syndrome (Ivanhoe & Reistetter, 2004). The velocity dependency in spasticity is a key
distinguishing feature from other similar motor disorders in which there is changed resistance to
passive movement at a joint, such as in the rigidity often present in people with Parkinson’s
disease. Normally, in an unperturbed central nervous system, any resistance observed in the full
range of joint movement should be solely due to biomechanical factors and electromyography
activity would not be elicited. In spasticity, however, there is damage to the corticospinal tracts,
which results in an increase of stretch reflexes that are normally latent.
In essence, spasticity is manifested largely by overactive neural input to muscles, which
causes excessive muscle contraction. This neural over-activity is a result of two underlying
mechanisms: hyperreflexia and brainstem upper motor neuron over activity. In hyperreflexia,
there is an absence of corticospinal inhibition onto lower motor neurons, which evokes a
heightened reflexive response. The lack of corticospinal inhibition furthermore produces an
excessive lower motor neuron response to muscle spindle input. Likewise, lesions that disinhibit
the reticulospinal and/or vestibulospinal tracts result in brainstem overactivity (Ivanhoe &
Reistetter, 2004). Spasticity becomes problematic when it interferes with postural alignment,
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activities of daily living, sleep, or produces pain or discomfort (Lundy-Ekman, 2013). Clinically,
spasticity has been delineated into both positive and negative symptoms. The conglomerate of
positive and negative features of spasticity comprises the upper motor neuron syndrome. Positive
aspects of spasticity include increased muscle tone, exaggerated stretch reflexes, positive
Babinski sign, clonus, and flexor/extensor spasms. Negative features encompass loss of a
particular functional capacity that is ordinarily controlled by the lesioned area of the brain, which
include loss of strength, dexterity, and motor control (Biering-Sorensen, Nielsen, & Klinge,
2006). The intricate pathophysiology of spasticity has obscured how clinicians define and
identify spasticity in the clinical setting.
The primary objective in clinical treatment approaches for spasticity management is
premised on modifying the degree of muscle imbalance through weakening the contractile
effects of involuntary muscle over activity in a given pattern in order to prevent irreversible softtissue changes and tendon contractures (e.g., flexor or extensor synergy). There are a range of
both conservative treatments and interventional measures to achieve this, including occupational
and physical therapies, oral and intrathecal medications, surgery, and focal chemical denervation
with phenol, alcohol, and botulinum neurotoxin (BoNT).
Brunnstrom Recovery Stages
In 1970, Brunnstrom proposed sequential stages of motor recovery following stroke
based on the degree of spasticity and voluntary movement. Each stage progression indicates less
presence of spasticity and improved motor performance. Brunnstrom’s recovery stages are the
only stroke-specific assessment in tracking the progression of motor recovery following stroke.
Six stages of motor recovery have been described. In stage one, flaccidity is present and no
movements of the limbs can be initiated. In stage two, the basic limb synergies or some of their
components may appear as associated reactions or minimal voluntary movement responses may
9

be present and spasticity begins to develop. In stage three, the patient gains voluntary control of
the movement synergies, although full range of all synergy components does not necessarily
develop and spasticity is severe. In stage four, some movement combinations that do not follow
the synergies are mastered and spasticity begins to decline. In stage five, more difficult
movement combinations are possible as the basic limb synergies lose their dominance over
motor acts. Finally, in stage six, individual joint movements become possible (Brunnstrom,
1970). Brunnstrom’s stages of recovery have been widely utilized by clinicians, giving rise to a
multitude of standardized assessments used by both occupational and physical therapists in the
assessment of motor performance following the onset of stroke.

III. Methods
Study Design
This was a prospective, cross-sectional research study in which all data was be collected
during a single 2.5-hour experimental session. The Institutional Review Board at Northwestern
University and the University of Wisconsin-Milwaukee approved the project.
Subjects
Stroke subjects were recruited from the Clinical Neuroscience Research Registry, a
research database management system that is updated and maintained by clinicians at the
Rehabilitation Institute of Chicago (RIC), and research flyers were distributed near the
Milwaukee area.
Eligibility for participation in the study included any history of stroke without regard to
time elapsed from onset, upper extremity weakness or loss of function, as well as diagnosed
spasticity in the elbow flexors and extensors in adults between the ages of 18-85. Exclusion
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criteria included presence of orthopedic impairment of the shoulder, elbow, wrist, or hand joints;
pain in any of the aforementioned musculoskeletal regions, or severe cognitive deficits that limit
ability to follow simple commands.
Clinical Assessment
Before the motion caption data collection, each subject’s non-paretic and paretic arms
was evaluated for clinical assessments including light touch sensation, isometric muscle strength,
spasticity, motor function and overall health status following stroke.
Light touch sensation was measured at 3 locations on the arm using the SemmesWeinstein monofilaments 5PC touch-test hand kit (2.83, 3.61, 4.31, 4.56, and 6.65) (Sammons
Preston Rolyan, Germantown, WI) at the upper arm, forearm, and hand. Results from touch
sensation were classified as intact if all sensation tests were normal; impaired if any of the tests
indicated sensation loss; and absent if patients could not identify the largest monofilament at any
of the testing locations.
Maximum isometric muscle strength was tested using the Lafayette hand-held muscle
tester (Lafayette Instruments, Lafayette, IN) in 2 upper limb movements: elbow flexion and
extension.
Severity of spasticity was assessed using the modified Ashworth Scale (MAS)
(Bohannon & Smith, 1987). Each subject’s elbow was quickly and passively stretched by an
occupational therapist. Spasticity is manifested by a catch angle and resistance to passive stretch.
The degree of spasticity was rated using ordinal response categories using a scale of 0 to 5,
where “0” corresponds to no increase in muscle tone (no spasticity) and “5” indicating that the
affected joint is highly rigid during flexion or extension (severe spasticity).
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We evaluated the upper limb motor function using the Fugl-Meyer Assessment scale –
upper extremity subscale (FM-UE) (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975), a
scale based on the theoretical framework of the Brunnstrom recovery scale describing the
recovery phases following stroke and is widely used in both clinical and research settings. The
FM-UE is composed of 33 tasks with a 3-point rating scale (0 to 2) that assesses reflex-activity
(3 items), dynamic movement within flexor and extensor synergy patterns (15 items), wrist
stability (5 items), hand function (7 items), and coordination (3 items). The score range of the
FM-UE is from 0 to 66, with higher measures representing higher levels of functionality. The
FM-UE subscale has excellent interrater reliability (r = 0.995-0.996) (Duncan, Propst, & Nelson,
1983; Gladstone, Danells, & Black, 2002).
The Stroke Impact Scale (SIS) was administered to subjects to evaluate how the stroke
impacted the subject’s health and life. The SIS is a 59-item measure that assesses eight different
domains: strength (4 items), hand function (5 items), ADL/IADL (10 items), mobility (9 items),
communication (7 items), emotion (9 items), memory and thinking (7 items), and
participation/role function (8 items). Each item is rated in a 5-point Likert scale in terms of
difficulty the patient has experienced in completing each item. An additional question asking the
patient to rate the recovery from their stroke on a scale of 0-100 is included at the end of the
questionnaire. The questionnaire has established test-retest reliability, ranging from adequate to
excellent (ICC = 0.70-0.92, except for the emotion domain, ICC = 0.57). Inter-rater reliability is
reported as excellent for the hand function (ICC = 0.82) and mobility domains (ICC = 0.80),
adequate for strength (ICC = 0.61), ADL/IADL (ICC = 0.64), and the memory and thinking (ICC
= 0.43) domains, and poor for the communication (ICC = 0.39), emotion (ICC = 0.17), and
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social participation (ICC = 0.29) domains (Carod-Artal, Ferreira Coral, Stieven Trizotto, &
Menezes Moreira, 2009; Duncan et al., 1999).
Experimental Setting
The Vicon motion capture system (7 Vicon MCam2 Cameras with 1.3 Megapixels) was
used to record the motion of reflective markers affixed to the upper arms and trunk. Subjects
were instructed to sit on a stationary chair with neither back nor arm support. The predominant
head axis of the global coordinate system, the Y axis, is defined as the forward facing direction
(front-back). The secondary X axis is the lateral axis from right to left, orthogonal to the Y axis.
The third Z axis follows the right-thumb rule, pointing up (vertical to the floor) and is orthogonal
to both the X and Y axes. Kinematic data was recorded at a sampling rate of 120 Hz.
Reflective Marker Placement
The Vicon Plug-In-Gait upper body model (see Appendix 1) for each subject
encompassed the trunk, upper extremities, and head, and was made using twenty-nine spherical
reflective markers. The markers were attached to the body using double-sided adhesive tape.
Bilaterally, markers will be placed on the acromion, inferior angle of the scapula, lateral
humerus, lateral epicondyle of the humerus, forearm, wrist (radial and ulnar aspects), and the
base of index finger. The trunk is defined at C7 of the cervical column, T10 of the thoracic spine,
the jugular notch, the sternum, and the sacrum. The hips are bilaterally defined at the anterior
superior and the posterior superior iliac spine. Markers defining the bilateral anterior and
posterior head will be fixed to a head band that each subject will wear.
Electromyography (EMG) Sensor Placement
A total of four EMG sensors (Delsys, Natick, MA) were affixed with adhesive tape
bilaterally to the muscle bellies of the biceps and triceps of both the affected and unaffected arm
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to record muscle activity. EMG placement sites were cleaned with alcohol wipes to remove dead
skin cells and maintain signal strength. These two sites were selected to assess the presence of
flexor or extensor spasticity, specifically.
Tasks during Motion Capture
A standard protocol was administered to each subject, and both sides of the upper body
were tested. The contralateral side (non-paretic) was precedent, and subjects were told to attempt
to duplicate each task with the paretic arm.
Active range of motion (AROM). The clinician instructed the subject to attempt to move
the paretic arm into all arm planes of movement to assess AROM. Ranges at the shoulder joint
(shoulder flexion), elbow joint (elbow flexion/extension), and wrist joint (wrist
flexion/extension) were calculated.
Passive stretch of the elbow. The clinical passive stretching test was performed by the
same occupational therapist who initially evaluated the subjects’ spasticity. The catch angle (in
degrees) was defined as the elbow position at which the therapist initially encountered resistance
of the paretic arm. The kinematic data corroborated this position, for the position was also the
point at which elbow angular velocity suddenly declined. The resistance to passive stretching
was quantified by the stretch duration (in seconds) that the therapist needed to complete a single
stretching test: from maximum elbow flexion to full extension (a test of flexor spasticity), and
from full extension back to maximum flexion (a test of extensor spasticity).
Finger-to-Nose (F-to-N) Reaching Task. Reaching is the most essential movement of
upper limb function involving the shoulder and elbow. Reaching performance is critical since the
arm needs to be placed in the desired position to support hand activities, such as grasping and
manipulating objects. A rhythmic F-to-N reaching task was used to assess the overall arm
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function. For this task, a height-adjustable target was positioned at the subject’s shoulder height,
oriented at the center of the body, and at about 90% of the extended arm length. Subjects were
instructed to touch the target with their index fingers and then touch their noses as many times as
possible within a 30s period. One repetition of F-to-N is the movement from the nose to the
target and then back to the nose. We define several variables of interest. The relative
completeness of the reaching movement, which we will call the path ratio (PR), is the ratio of the
paretic arm’s maximal reaching distance in the Y-axis from nose to target to that of the
contralateral arm. Maximum path ratio will be set to 1. Efficiency of arm movement is as the
total time needed to complete 5 repetitions of the F-to-N movement.
Note that the experiment setup for the case study at University of Wisconsin-Milwaukee
mirrored that of the experimental setup at the Rehabilitation Institute of Chicago except the
following minor differences. The Vicon motion capture system (6 Vicon Bonita Cameras with 16
Megapixels) was used to record the motion of reflective markers. In addition, the clinician placed
and held a mini force sensor on the medial and lateral aspects of the subject’s wrists to collect the
level the force exerted on the upper limb tested during administration of the passive stretch.
Figure 2 shows the experimental setup, sensor placements, and beginning and end positions
when performing the passive stretching during the motion capture at the University of
Wisconsin-Milwaukee site.
Analysis
The motion-caption data was digitally low-pass filtered at 6Hz with a 4th-order finiteimpulse response filter to attenuate high-frequency noise without altering the signal phase. To
examine the relationships between the MAS and selected variables, we first inspected the scatter
plots (a) between the MAS and residual impairments (active range of motion of shoulder flexion,
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elbow, and wrist, and muscle strength of the elbow flexion and extension), (b) between the MAS
and functional limitations as measured by Fugl-Meyer upper extremity assessment, finger to
nose movement, and ability to grasp a bottle of water, and (c) between the MAS and overall
health status following stroke as measured by the Stroke Impact Scale. Pearson correlation
coefficients and Spearman correlation coefficients were computed. One-way ANOVA will be
used to compare the overall mean differences of the selected variables by MAS ratings. The
significant level was set at 0.05. Post-hoc analysis will not be used as follow-up procedures due
to small sample size per MAS ratings.
To inspect whether there are potential kinematic values or physiological responses that
can be used to identify the characteristics of the passive stretch (passive stretch duration, catch
angle, electromyography response), a case study was used to compare the performance between
affected arm and unaffected arm during passive stretch. For this thesis, Vicon data was processed
following the Plug-In-Gait model within the Nexus software. The kinematic data was graphed
with the elbow joint angle as a function of time. Both EMG data and force data are presented as
raw data to inspect the differences between the affected arm and unaffected arm during passive
stretch.

IV. Results
Relationship between MAS and residual impairments. Figure 3 shows the scatterplot
between MAS scores and residual impairments (active range of motion of shoulder, elbow and
wrist, and muscle strength of elbow flexion and extension). Overall, results showed that stroke
subjects who had more severe spasticity tended to have reduced range of motion at the shoulder
(flexion) (Pearson correlation coefficient rp = -.601; Spearman correlation coefficient rs = -.607),
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elbow (rp = -.436; rs = -.495) and wrist (rp = -.206; rs = -.305) joints, as well as reduced muscle
strength for elbow flexion (rp = -.547; rs = -.618). The relationship between the MAS scores and
the muscle strength for elbow extension was weak (rp = -.160; rs = -.191).
Relationship between MAS and functional limitations. Figure 4 summarizes the results of
the relationship between the MAS scores and the FM-UE subscale. Analysis between the FM-UE
subscale and MAS revealed a significant negative correlation. The strongest correlation occurred
between the FM-UE total score (rp = -0.817; rs = -0.806), while the weakest correlation amongst
all subscales occurred between coordination subscale (rp = -0.696; rs = -0.684). A one-way,
between-subjects design ANOVA showed significant mean differences between MAS scores and
all FM-UE subscales: the FM-Arm subscale (F4,15 = 17.4, p < .001), the FM-Wrist subscale (F4,15
= 4.3, p < 0.016), the FM-Hand subscale (F4,15 = 4.8, p < 0.011), the FM-Corr subscale (F4,15 =
4.4, p < 0.015) as well as FM-Total Score subscale (F4,15 = 12.6, p < 0.001). Overall, there was a
tendency for increased levels of spasticity per scoring of the MAS to result in decreased motor
performance as measured by the FM-UE subscale.
Relationship between MAS and overall health status. Figure 5 demonstrated the
relationship between the MAS scores and overall health status per the Stroke Impact Scale
subscales. There was a moderate negative correlation between MAS score and the hand subscale
(rp = -0.543; rs = -0.576), indicating that a higher MAS score may be indicative of the magnitude
of impairment in the hand. No significant relationships were demonstrated between the
remaining subscales of the Stroke Impact Scale, suggesting that there is little to no relationship
between MAS scores and overall health status.
Case Study. By inspecting the motion capture raw data, there was a marked increase in
the EMG response when the subjects affected limb is stretched into full elbow extension (Figure
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6, supplement with one Video clip), such phenomenon was not observed when stretching the unaffected limb.

V. Discussion
The strong correlation between MAS scores and the residual impairments as well as the
FM-UE subscale suggests that a higher MAS score may be indicative of the general stage of
motor recovery following incurrence of a stroke. However, the severity of spasticity may not
predict an individual’s overall health status as measured using the Stroke Impact Scale.
To the best of our knowledge, there is no previous literature explicitly examining the
correlation between the MAS and the Fugl Meyer Assessment and Stroke Index Scale. However,
previous studies have ascertained similar results regarding the MAS and residual upper extremity
impairment (Denham, 2008). Previous studies have proposed that effectively operationalizing the
definition of quality of life and overall health status could contribute to more objective
measurement of the relationship between spasticity management and health status and quality of
life (Gianino JM, York MM, Paice JA, et al., 1998).
While results from this study were variable, it was evident that there were several
significant correlations between MAS scores and functional impairments, as well as
neurophysiological variables such as EMG through inspection of raw EMG data and the motion
capture videos. One previous study, however, confounds these findings. Alibiglou et al. (2008)
investigated the quantitative measures of spasticity and their relationship to the MAS
demonstrated a lack of significant correlation between the MAS and quantitative measures of
stroke including neural and muscular components (Alibiglou et al., 2008). In short, the study
reported that the MAS does not provide reliable information about quantitative measures
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associated with spasticity or about its contributing components. Because spasticity is an intricate
neurophysiological phenomenon and the MAS does not have adequate objectivity in accurately
quantifying clinical assessment of spasticity, it is clear that the inconspicuous results in this
previous study and others alike are faced with an aggregate of challenges in validly and reliably
quantifying spasticity.
The results gleaned from the case study suggested that there is significance in the amount
of spasticity present and the magnitude of EMG produced during passive stretching. Though we
were unable to clearly examine the effect of velocity and force on the amount of produced
resistance during passive stretching, it is likely that increased force and velocity is conducive to
an increased tonic reflex (catch angle) and resistance force through passive stretching.
Future directions of research to examine the MAS and functional impairments through
using motion capture and EMG should increase the case study into case series by collecting
stroke subjects within each MAS strata to more closely inspect these quantitative measures and
produce more clear results.

VI. Conclusions
The strong correlation between MAS scores and the residual impairments as well as the
FM-UE subscale suggests that a higher MAS score may be indicative of the general stage of
motor recovery following incurrence of a stroke. Additionally, there was a marked increase in
EMG activity through passive stretching of the affected limb into full elbow extension;
conversely, such a phenomenon was not observed in the unaffected limb.
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Limitations and Potential Contributions
Because this particular study has no specificity in regard to the amount of time elapsed
following the onset of stroke, it may be difficult to generalize the study’s findings to a large
population because spasticity can evolve over the course of time. Because functional recovery
following strokes typically occurs during the first three months following onset, it would be
important to include a more heterogeneous group of participants for future studies. Stroke
generally affects older adults, however, there has been a growing trend of younger people
incurring stroke, and the sample size does not account for this emerging trend. Furthermore, the
modest sample size further constrains the amount of generalizability. The use of two force
sensors instead of one as well as increasing the amount of motion capture cameras to minimize
the gaps in the data frames could also increase objectivity and fidelity. Utilizing an organic
motion capture system and more motion capture cameras could additionally improve the findings
from this study. Finally, incorporating an independent MAS clinical assessment evaluator (blind
assessor) could improve the reliability of this study.
This study has the potential to reduce the subjectivity of the MAS and translate it into
functional values, a highly prominent clinical assessment for spasticity in stroke patients and
other populations where spasticity is present such as individuals with stroke, multiple sclerosis,
cerebral palsy, traumatic brain injury, or spinal cord injury. Reducing the subjectivity will yield
an increased ability for the clinician to appropriately address spasticity treatment, track progress
in treatment plans, and more clearly illustrate therapeutic outcomes. Additionally, accurate
measurement of spasticity as a result eradication of subjective MAS components will enable
clinical researchers to more easily illustrate efficacy of studies examining novel therapeutic or
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pharmacological treatment strategies for persons with spasticity while using the MAS as an
outcome measure.
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TABLES/FIGURES
Table 1. Ashworth Scale and Modified Ashworth Scale.
Score
Ashworth Scale (1964)
Modified Ashworth Scale
Bohannon & Smith (1987)
0 (0)

No increase in tone

No increase in muscle tone

1 (1)

Slight increase in tone giving a

Slight increase in muscle tone, manifested

catch when the limb was moved in

by a catch and release or by minimal

flexion or extension

resistance at the end of the range of
motion when the affected part(s) is moved
in flexion or extension

1+ (2)

Slightly increase in muscle tone,
manifested by a catch, followed by
minimal resistance throughout the
remainder (less than half) of the ROM
(range of movement)

2 (3)

More marked increase in tone but

More marked increase in muscle tone

limb easily flexed

through most of the ROM, but affected
part(s) easily moved

3 (4)

4 (5)

Considerable increase in tone –

Considerable increase in muscle tone –

passive movement difficult

passive movement difficult

Limb rigid in flexion or extension

Affected part(s) rigid in flexion or
extension

Abbreviations: ROM=range of movement
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Table 2. Subject demographics from Rehabilitation Institute of Chicago data collection sample (n
= 20)
Min

Max

Mean

SD

Age (years)

27.0

70.0

57.4

10.3

Time Since Onset of Stroke (months)

12.0

433.0

151.8

113.9

Height (m)

1.60

1.93

1.73

8.9

Weight (kg)

50.0

135.0

80.3

17.2

BMI (kg/m^2)

18.8

36.0

26.7

4.3

Abbreviations: SD = standard deviation; min = minimum; max = maximum; BMI = body mass
index as calculated by the subject’s weight in kilograms (kg) divided by the square of height in
meters (m).
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Table 3. Relationship between MAS scores and residual impairments.
N

Mean

SD

Pearson (rp) and

ANOVA

Spearman's (rs)
Correlation
Shoulder Flexion (º)

Elbow Flexion (º)

Wrist Flexion (º)

Elbow Flexion (kg)

Elbow Extension (kg)

19

19

17

19

17

99.8

53.7

-44.0

7.6

10.0

37.655

16.223

28.131

5.178

3.528

24

rp = -.601

F4, 14 = 5.8

rs = -.607

p < 0.006

rp = .436

F3, 15 = 1.4

rs = .495

p < 0.287

rp = .206

F3, 13 = .427

rs = .305

p < 0.737

rp = -.547

F3, 15 = .3

rs = -.618

p < 0.844

rp = -.160

F3, 13 = .427

rs = -.191

p < 0.737

Table 4. Relationship between MAS and FM-UE subscales.
N

Mean

SD

Pearson (rp)

ANOVA

and
Spearman's
(rs)
Correlation
FM-Arm

FM-Wrist

FM-Hand

0

5

32.2

2.8636

rp = -.815

1

5

26.6

6.6558

rs = -.829

2

1

5

.

4

7

15

5.164

5

2

5.5

3.5355

Total

20

20.75

10.6468

0

5

7

4.4721

rp = -.696

1

5

5.8

4.0866

rs = -.754

2

1

0

.

4

7

0.571

1.5119

5

2

0

0

Total

20

3.4

4.26

0

5

9.8

4.7645

rp = -.714

1

5

8.2

4.3243

rs = -.728

2

1

1

.

4

7

2.286

2.7516

5

2

0.5

0.7071

25

F4,15 = 17.4, p < .001

F4,15 = 4.3, p < 0.016

F4,15 = 4.8, p < 0.011

FM-Corr

FM-Total

Total

20

5.4

5.0409

0

5

3.8

2.2804

rp = -.696

1

5

3

1.8708

rs = -.684

2

1

0

.

4

7

0.571

0.9759

5

2

0

0

Total

20

1.9

2.1497

0

5

52.8

13.0652 rp = -.817

1

5

43.6

14.1174 rs = -.806

2

1

6

.

4

7

18.429

7.5246

5

2

6

2.8284

Total

20

31.45

20.4874

F4,15 = 4.4, p < 0.015

F4,15 = 12.6, p < 0.001

Abbreviations: FM-UE = Fugl-Meyer upper extremity; SD = standard deviation.
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Table 5. Relationship between MAS scores and overall health status.
N

Mean

SD

Pearson (rp) and ANOVA
Spearman's (rs)
Correlation

Subscale 1 Strength

19

12.9

2.7501

rp = -.186

F4,14 = 3.1, p < 0.053

rs = -.281
Subscale 2 Cognition

19

32.9

2.6893

rp = .007

F4,14 = 0.2, p < 0.925

rs = .064
Subscale 3 Emotion

19

34.7

6.7521

rp = -.009

F4,14 = 0.5, p < 0.724

rs = .073
Subscale 4 Speech

19

34.3

1.1471

rp = .081

F4,14 = 0.2, p < 0.944

rs = .223
Subscale 5 ADL

19

40.8

5.7547

rp = .083

F4,14 = 0.4, p < 0.819

rs = .114
Subscale 6 Walk

19

40.9

3.3177

rp = -.190

F4,14 = 2.5, p < 0.094

rs = -.203
Subscale 7 Hand

19

12.7

6.7646

rp = -.543

F4,14 = 2.4, p < 0.097

rs = -.576
Subscale 8 Social

19

34.1

5.227

rp = .170

F4,14 = 0.2, p < 0.939

rs = .268
Total Score

19

2432.1

20.9858

rp = -.162
rs = -.188

Abbreviations: SD = standard deviation.
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F4,14 = 0.9, p < 0.506

Upper motor neuron (UMN) lesion
Abnormal muscular
contraction

Weakness

Immobilization at
Dynamic
Static
short muscle length
§ Spasms
§ Spasticity
§ Co-contraction
§ Spastic dystonia
Biomechanical changes
§ Clonus
§ Reduced compliance
§ Associated reaction
§ Contracture
§ Flexor withdrawal
Hypertonia + Reduced ROM
Abnormal postures
Impaired function

Figure 1. A model of the interaction between neural and biomechanical components of
hypertonia in the upper motoneuron syndrome (Barnes & Johnson, 2001)
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Mini force sensor
A

C

B

D

Electromyography
sensor

Figure 2. Motion capture experimental set-up at the University of Wisconsin-Milwaukee
Innovation Accelerator motion analysis laboratory
Figure 2A. The beginning position of the MAS is displayed. The clinician supports the spastic
upper extremity while passive stretching is initiated to assess for flexor/extensor spasticity. 2B.
The clinician places the mini force sensor on the medial aspect of the wrist during passive
stretching. 2C. Placement of reflection motion capture sensors at various anatomical landmarks
of the upper extremity. 2D. Placement of the electromyography sensor on the triceps. An
electromyography sensor will also be placed on the muscle belly of the biceps.
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Elbow Flexion
Muscle Strength (kg)

Shoulder Flexion
AROM (°)

200
150
100
50
0
0

1

2

3

4

5

140

Elbow Extension
Muscle Strength (kg)

Elbow AROM (°)

MAS Score

120
100
80
60
40
20
0
0

1

2

3

4

5

MAS Score

Wrist AROM (°)

20
18
16
14
12
10
8
6
4
2
0
0

1

2

3

4

5

4

5

MAS Score

20
15
10
5
0
0

1

2

3

MAS Score

140
120
100
80
60
40
20
0
0

1

2

3

4

5

MAS Score

Figure 3. Relationship between Modified Ashworth Scale and residual impairments (active range
of motion of shoulder flexion, elbow, and wrist, and muscle strength of elbow flexion and
extension).
Abbreviations: AROM = active range of motion; MAS = Modified Ashworth Scale.
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14
10

FM-Arm

FM-Wrist

12
8
6
4
2
0
0

1

2

3

4

40
35
30
25
20
15
10
5
0

5

0

1

16
14
12
10
8
6
4
2
0
0

1

2

3

4

5

4

5

4

5

4

5

7
6
5
4
3
2
1
0
0

1

MAS Score

2

3

MAS Score

70

30

60

25

5 F-to-N (s)

FM-Total

3

MAS Score
FM-Coordination

FM-Hand

MAS Score

2

50
40
30
20
10
0

20
15
10
5
0

0

1

2

3

4

5

0

MAS Score

1

2

3

MAS Score

Figure 4. Relationship between MAS and functional limitations as measured by Fugl-Myer upper
extremity assessment, finger to nose movement, and ability to grasp a bottle of water.
Abbreviations: FM = Fugl-Meyer upper extremity assessment subscale; MAS = Modified
Ashworth Scale; F-to-N = finger-to-nose.
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300

SIS-Total

250
200
150
100
50
0
0

1

2

3

4

5

MAS Score

Figure 5. Relationship between MAS and overall health status following stroke as measured by
the Stroke Impact Scale subscales.
Abbreviations: SIS = Stroke Impact Scale (the SIS is a 59-item measure with 8 different domains
wherein each subject rated each item on a 5-point Likert scale in terms of the difficulty they
experienced in completing each item; summative scores were generated for each domain with a
range of 0-100 with a higher score indicating less difficulty); ADL = activities of daily living.
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Appendix
Plug-in-Gait Marker Placement
Head Markers
LFHD

Left front head

Located approximately over the left temple

RFHD

Right front head

Located approximately over the right temple

LBHD

Left back head

Placed on the back of the head, roughly in a horizontal plane
of the front head markers

RBHD

Right back head

Placed on the back of the head, roughly in a horizontal plane
of the front head markers

Torso Markers
C7

7th Cervical

Spinous process of the 7th cervical vertebrae

Vertebrae
T10

10th Thoracic

Spinous Process of the 10th thoracic vertebrae

Vertebrae
CLAV

Clavicle

Jugular Notch where the clavicles meet the sternum

STRN

Sternum

Xiphoid process of the Sternum

RBAK

Right Back

Placed in the middle of the right scapula. This marker has no
symmetrical marker on the left side. This asymmetry helps
the autolabeling routine determine right from left on the
subject.

Arm Markers
LSHO

Left shoulder

Placed on the Acromio-clavicular joint

marker
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LUPA

Left upper

Placed on the upper arm between the elbow and shoulder

arm marker

markers.
Should be placed asymmetrically with RUPA

LELB

Left elbow

Placed on lateral epicondyle approximating elbow joint axis

LFRA

Left forearm

Placed on the lower arm between the wrist and elbow

marker

markers. Should
be placed asymmetrically with RFRA

LWRA

Left wrist

Left wrist bar thumb side

marker A
LWRB

Left wrist

Left wrist bar pinkie side

marker B
LFIN

Left fingers

Actually placed on the dorsum of the hand just below the
head of the
second metacarpal

Pelvis
LASI

Left ASIS

Placed directly over the left anterior superior iliac spine

RASI

Right ASIS

Placed directly over the right anterior superior iliac spine

LPSI

Left PSIS

Placed directly over the left posterior superior iliac spine

RPSI

Right PSIS

Placed directly over the right posterior superior iliac spine

Left knee

Placed on the lateral epicondyle of the left knee

Leg
Markers
LKNE
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LTHI

Left thigh

Place the marker over the lower lateral 1/3 surface of the
thigh, just below the swing of the hand, although the height is
not critical.

LANK

Left ankle

Placed on the lateral malleolus along an imaginary line that
passes through the transmalleolar axis

LTIB

LTOE

Left tibial

Similar to the thigh markers, these are placed over the lower

wand

1/3 of the shank to determine the alignment of the ankle

marker

flexion axis

Left toe

Placed over the second metatarsal head, on the mid-foot side
of the equinus break between fore-foot and mid-foot

LHEE

Left heel

Placed on the calcaneous at the same height above the plantar
surface of the foot as the toe marker
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